New horizons in the treatment of irritable bowel syndrome

Drugs of Today

Volumn 35, Issue 1, 1999, Pages 5-12

  Bamba, Tadao ^a   Fuse, Kenji ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DOPAMINE; KAPPA OPIATE RECEPTOR AGONIST; LAXATIVE; LEUPRORELIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; NORADRENALIN; ONDANSETRON; POLYCARBOPHIL CALCIUM; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; DIET THERAPY; GASTROINTESTINAL MOTILITY; INCIDENCE; INTESTINE MOTILITY; IRRITABLE COLON; PSYCHOSOMATIC DISORDER; REVIEW;

EID: 0032978228     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.1.522950     Document Type: Review

References (20)

1. Tompson, W.G., Creed, F., Drossman, D.A. et al. Functional bowel disease and functional abdominal pain. Gastroentrol Int 1992, 5: 75-91.
2. Bamba, T., Koyama, S., Saito, Y. The disturbance of defecation. Intern Med 1996, 35: 53-5.
3. Mertz, H., Naliboff, B., Munakata, J. et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109: 40-52.
4. Whitehead, W.E., Schuster, M.M. Irritable bowel syndrome: Definition of the syndrome and relation to other disorders. Physiological and psychological mechanism. In: Behavioral and Physiological Basis for Treatment of Gastrointestinal Disorders. Whitehead, E.E. Schuster, M.M. (Eds.). Academic Press: New York 1985, 155-209.
5. Kellow, J.E., Evans, P.R. Management of irritable bowel syndrome. J Gastroenterol Hepatol 1993,8:287-93.
6. Wilde, K., Markham, A. Ondansetron: A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996, 52: 773-94.
7. Steadman, C.J., Talley, N.J., Phillips, S.F. et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study. Mayo Clin Proc 1992, 67: 732-8.
8. Maxton, D.G., Morris, J., Whorwell, P.J. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 1996, 10: 595-9.
9. 3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7: 543-51.
10. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7: 175-80.
11. 4 antagonism in irritable bowel syndrome (IBS): Effect of SB-207266-A on rectal sensitivity and small bowel transit. Gut 1997, 41 (Suppl. 3): A26.
12. Junien, J.L., Riviere, P. The hypersensitive gut-peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995, 9: 117-26.
13. Dapoigny, M., Abitbol, J.L., Fraitag, B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Dig Dis Sci 1995, 40: 2244-8.
14. Farthing, M.J.G. New drugs in the management of the irritable bowel syndrome. Drugs 1998, 56: 11-21.
15. Danhof, I.E. Pharmacology, toxicology, clinical efficacy and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy 1982, 2: 18-28.
16. Toskes, P.P., Connery, K.L., Ritchey, T.W. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7: 87-92.
17. Masamune, O., Miwa, T., Fukutomi, H. Clinical phase III comparative study of calcium polycarbophil tablets in irritable bowel syndrome: A double-blind study in comparison with torimebutine maleate. Jpn Pharmacol Ther 1998, 26: 63-92.
18. Mathias, J.R., Clench, M.H., Reeves-Darby, V.G. et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease: Double-blind, placebo-controlled study. Dig Dis Sci 1994, 39: 1155-62.
19. Mathias, J.R., Clench, M.H., Roberts, P.H. et al. Effect of leuprolide acetate in patients with functional bowel disease: Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci 1994, 39: 1163-70.
20. 3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997, 11: 561-8.